“Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: correlations between patient-reported outcomes and clinical responses in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2”, J of Skin, vol. 6, no. 6, p. s63, Nov. 2022, doi: 10.25251/skin.6.supp.63.